2010 HESI ANNUAL MEETING
MAY 11-13, 2010
HYATT REGENCY RESTON HOTEL
RESTON, VIRGINIA
Workshop Presentations
Assembly of Members
Welcome to HESI Assembly of Members & Board of Trustees
Dr. Marc Bonnefoi, sanofi aventis
Introduction: Strengthening HESI’s impact through AOM and BOT involvement.
Dr. Michael Holsapple, ILSI HESI
Highlights of HESI Outreach
Outreach in Japan
Ms. Ayako Takei, ICaRuS Japan Limited
Outreach in Europe
Ms. Syril Pettit, ILSI HESI
Dr. Michelle Embry, ILSI HESI
Assembly of Members Business Meeting
HESI Scientific Mapping
Ms. Nancy Doerrer, ILSI HESI
Emerging Issues Session
Welcome
Dr. Bhaskar Gollapudi, The Dow Chemical Company
Reports on Existing HESI Emerging Isssues Subcommittees
Methodologies for Intermittent or Short-term Exposure to Carcinogens (MISTEC)
Dr. Rory Conolly, US EPA National Center for Computational Toxicology
Distinguishing Adverse from Adaptive, Non-functional and Pharmacological Changes in Toxicology Studies
Dr. Douglas Keller, sanofi-aventis
Identification of Pharmaceuticals for Validation of TOXCAST™
Dr. Robert Chapin, Pfizer, Inc.
State of the Science: Evaluating Epigenetic Changes
Dr. Karen Augustine, Bristol-Myers Squibb Company
New Topic Areas for Consideration By HESI Constituency
Causality and Epidemiology Studies
Dr. Stephen Cole, University of North Carolina
Dr. Carol Burns, The Dow Chemical Company
Causality and Epidemiology: Role of HESI
Dr. Carol Burns, The Dow Chemical Company
Dr. Stephen Cole, University of North Carolina
Association of Autoimmunity with Adjuvants in Vaccines
Dr. Sarah Gould, sanori-pasteur
Dr. Jan Willem van der Laan, RIVM
Role of HESI in Adjuvants and Autoimmunity
Dr. Sarah Gould, sanofi-pasteur
Dr. Jan Willem van der Laan, RIVM
Next Steps
Dr. Bhaskar Gollapudi, The Dow Chemical Company
State-Of-The-Science Within HESI Session
Technical Committee on Cardiac Safety
Project Committee on Translational Imaging in Safety Assessment
In Vivo Imaging: Gaps and Opportunities
Dr. David Brewster, Hoffman-La Roche
Project Committee on Translational Imaging in Safety Assessment
Dr. Allan G. Johnson, Duke University
Scientific Session
HESI New Strategies and Approaches for Assessing Genetic Toxicity and Its Role in Human Risk Assessment
Introduction
Dr. James Kim, HESI
Current Strategies in Assessing Genotoxic Risk
Dr. Kerry L. Dearfield, U.S. Department of Agriculture
Need for a new Approach to Genetic Toxicity Assessment: Lessons Learned and New Opportunities
Dr. James T. MacGregor, Toxicology Consulting Services
Approaches to Follow-up Positive Results in Genetic Toxicology Tests in the Context of Human Risk Assessment
Dr. Veronique Thybaud, sanofi-aventis
New Technologies to Predict Genotoxic Risk in Humans
Dr. David Jacobson-Kram, U.S. Food and Drug Administration
Beyond Positive or Negative: A Quantitative Approach for Interpreting Genotoxicity Data
Dr. B. Bhaskar Gollapudi, The Dow Chemical Company
Optimal Design for in vivo Mutation Studies to Inform Cancer Mode-of-Action Assessment
Dr. Martha M. Moore, U.S. Food and Drug Administration/NCTR
